The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | Real-world outcomes of patients with mantle cell lymphoma
Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, analyses the findings from a study which focuses on patients with mantle cell lymphoma (MCL). Dr Riedell noted a high application of R-CHOP as induction therapy, however multiple data sets suggest that bendamustine-based therapy may be superior to R-CHOP based treatments. Dr Riedell also touches on the reduced utilization of autologous stem cell transplants in the community setting, indicating that this is an area where awareness is required. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Peter A. Riedell, MD, reports research support/funding from Celgene/BMS, Kite Pharma, Inc./Gilead, MorphoSys, Calibr, Xencor, Tessa Therapeutics, and Novartis Pharmaceuticals Corporation; speaker’s bureau from Kite Pharma, Inc./Gilead and Bayer; consultancy on advisory boards from Verastem Oncology, Novartis Pharmaceuticals Corporation, Celgene/BMS, BeiGene, Karyopharm Therapeutics Inc., Takeda Pharmaceutical Company, and Bayer; honoraria from Novartis Pharmaceuticals Corporation.
